/Business Of Biotech

Business Of Biotech

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies. Sean also discusses FDA pathways, incentives, and agen...

Sobre

284

Episódios

English

Idioma

Inscritos

Reproduções

Episódios25

Inverter ordem de reprodução

Engineering B Cells With Immusoft's Sean Ainsworth

Dec 8, 2025·—

—

Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt

Dec 1, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a...

Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.

Nov 24, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific...

Biotech Funding And IPO Temperature Check With Create Medicine's Allan Shaw

Nov 17, 2025·—

—

We love to hear from our listeners. Send us a message. Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on...

Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier

Nov 10, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and...

Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.

Nov 3, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May...

BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals

Oct 27, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life...

BoB In South Florida: Anthony Japour, M.D., iTolerance

Oct 20, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- part three in a four part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- Anthony...

BoB In South Florida: Daniel Teper, NAYA Therapeutics

Oct 13, 2025·—

—

We love to hear from our listeners. Send us a message. In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're...

BoB In South Florida: Raquel Cabo, Miami Biotech Collective

Oct 6, 2025·—

—

We love to hear from our listeners. Send us a message. The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo...

The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott

Sep 29, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from...

Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham

Sep 22, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for...

Dye Drug Conjugates For Cancer With Lahjavida's Lyle Small

Sep 15, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Lyle Small, Founder and CEO at Lahjavida, a dye drug conjugate start-up, talks about creating the famous color-changing technology that...

Investing In The Biostack With Modi Ventures' Sahir Ali, Ph.D.

Sep 8, 2025·—

—

We love to hear from our listeners. Send us a message. On the Business of Biotech this week, Sahir Ali, Ph.D., founder and general partner at Modi Ventures, a family office investing at the intersection of technology...

Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Sep 1, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during...

Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.

Aug 25, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa...

Biotech Product Partnership with Coya Therapeutics' Arun Swaminathan, Ph.D. and Dr. Reddy's Milan Kalawadia

Aug 18, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique...

How To Hire And Build A Winning Executive Team With Occam Global's Bill Holodnak

Aug 11, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Bill Holodnak, Cofounder and CEO of Occam Global, a life sciences executive recruitment firm (and occasional investor), shares insights from...

The Generalist Biotech CEO With Seekyo's Oury Chetboun

Aug 4, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company...

Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.

Jul 28, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a...

Building An Efficient Biopharma With South Rampart Pharma's Hernan Bazan, M.D.

Jul 21, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development...

The Business And Science Of Obesity With Roger Cone, Ph.D., Founder Of Courage Therapeutics

Jul 14, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related...

BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies

Jul 7, 2025·—

—

We love to hear from our listeners. Send us a message. This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to...

How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland

Jun 30, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while...

FDA Trials And Tribulations With Connect Biopharma's Barry Quart

Jun 23, 2025·—

—

We love to hear from our listeners. Send us a message. On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key...